MétaCan
Menu
Back to cohort

Surgical management of the primary tumor in stage IV colorectal cancer: A validation study.

2015· article· en· W2249094632 on OpenAlexaffabout
Shahid Ahmed, Punam Pahwa, Selliah Kanthan, Anthony Fields, Duc Le, Kamal Haider, Bruce Reeder, Osama Ahmed, Riaz Alvi, Nayyer Iqbal, Tahir Abbas, Adnan Zaidi, F. Arnold, Sunil Kumar Yadav, Amer Sami, Anne Leis

Bibliographic record

VenueJournal of Clinical Oncology · 2015
Typearticle
Languageen
FieldMedicine
TopicColorectal Cancer Treatments and Studies
Canadian institutionsSaskatchewan Cancer AgencyUniversity of Saskatchewan
Fundersnot available
KeywordsMedicineBevacizumabHazard ratioFOLFOXFOLFIRIInternal medicineColorectal cancerProportional hazards modelSurgeryChemotherapyStage (stratigraphy)CancerOxaliplatinConfidence interval

Abstract

fetched live from OpenAlex

675 Background: The observational studies have demonstrated superior survival of patients with stage IV CRC who undergo surgical resection of the primary tumor (SRPT). Yet the results are not confirmed in the setting of a randomized controlled trial. Lack of randomization and failure to control the prognostic variables that affect survival including performance status (PS) are the major critiques to the findings of observational studies. Our group has demonstrated that SRPT improves survival of stage IV CRC patients, who were diagnosed between 1992-2005, independent of age and PS (Cancer. 2014;120:683). The current study is undertaken to validate our findings in patients who are treated with modern chemotherapy. Methods: A cohort of 569 patients with stage IV CRC diagnosed between 2006-2010 in Saskatchewan was evaluated. Cox regression model was used to adjust survival for important prognostic variables. Results: Median age was 69 years (59-95) and M:F was 1.4:1. 35% had ECOG PS of >1. 313 (55%) patients underwent SRPT. Median followup time was 11 months (inter-quartile range 2-26). 57.3% received chemotherapy, 91.4% received FOLFIRI or FOLFOX and 67% received anti-EGFR inhibitors and or bevacizumab. Median overall survival (OS) of patients who had SPRT and received chemotherapy was 27 months compared with 14 months if they did not have surgery (p<0.0001). Median OS of patients who received all active agents and had SPRT was 39 months (95% CI: 25.1-52.9). On multivariate analysis SRPT, hazard ratio (HR) for mortality of 0.44 (95% CI: 0.35-0.56), use of chemotherapy, HR 0.33 (95% CI: 0.26-0.43), metastasectomy, HR 0.43 (95% CI: 0.31-0.58), second line therapy, HR 0.50 (95% CI: 0.35-0.70), and third line therapy, HR 0.58 (95% CI: 0.41-0.83) were independently correlated with superior survival. Elevated alkaline phosphatase, (HR 1.50 (95% CI: 1.20-1.78), grade 3 tumor, HR 1.33 (95% CI: 1.10-1.62), leukocytosis, HR 1.32 (95% CI: 1.05-1.66), stage IVb disease, HR 1.31 (95% CI: 1.10-1.56), and ECOG PS>1, HR 1.30 (95% CI: 1.04-1.57) were correlated with inferior survival. Conclusions: Our study supports SRPT in patients with stage IV CRC who are treated with modern combination of chemotherapy and biologics.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.013
Threshold uncertainty score0.027

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.004
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.151
GPT teacher head0.480
Teacher spread0.329 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2015
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicColorectal Cancer Treatments and StudiesFrench-language works237,207